Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 9/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.48 |
| ▸ | CDK2 | P24941 | 10/20 | 0.48 |
| ▸ | CDK9 | P50750 | 10/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490763 | 0.78 | KIT (0.40) | FEN1ALOX5APCCNT1CDK9KIT | |
| SCHEMBL12343730 | 0.76 | PDGFRB (0.50) | KIT | |
| SCHEMBL12343418 | 0.76 | DHODH (0.39) | FEN1ALOX5APKIT | |
| SCHEMBL12343554 | 0.76 | MAP4K1 (0.44) | FEN1ALOX5APKIT | |
| SCHEMBL3489835 | 0.75 | MAP4K1 (0.45) | FEN1ALOX5APKIT | |
| SCHEMBL12343157 | 0.75 | ABL1 (0.44) | KIT | |
| SCHEMBL12343728 | 0.74 | KIT (0.54) | KIT | |
| SCHEMBL3489080 | 0.73 | MAP4K1 (0.58) | KIT | |
| SCHEMBL3490388 | 0.73 | AAK1 (0.45) | KIT | |
| SCHEMBL14877380 | 0.73 | FYN (0.49) | CCNT1CCNA2CDK2CDK9KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268994-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | SGX PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-2134179-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | FEN1 3153/4885ALOX5AP 4527/4885CCNT1 2017/4885 |
| US-20100036118-A1 | Fused Ring Heterocycle Kinase Modulators | MAP3K20, TTK, MAP3K19 | FEN1 3153/4885ALOX5AP 4527/4885CCNT1 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.